undamentalytics Newsletter
Sign in

Metagenomi Therapeutics, Inc. (MGX) stock

Add to watchlist

Add holding +

NASDAQ: MGX Nasdaq Biotechnology Next results ~November 11, 2026

Metagenomi Therapeutics, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

Under review: data-quality checks not passed.

Price vs value

Under review: data-quality checks not passed. We'll show the comparison once resolved.

Metagenomi Therapeutics, Inc. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders1 buying, 4 selling2 purchases and 13 sales by directors and officers, last 12 monthsInsider trades
  • Funds16 adding, 20 cuttingOf 11 active managers that changed their stake, 5 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Metagenomi Therapeutics files

Where Metagenomi Therapeutics stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $22m, down 50.7% on a year earlier, a smaller fall than the 51.8% decline a quarter earlier. Free-cash-flow margin fell to -392.0% from -231.0% a year earlier. Operating margin narrowed to -415.5% from -193.7%. It passes 2 of our 2 financial-health checks.

Our model value for Metagenomi Therapeutics is under review, so past values are not shown until it is resolved.

Source: 10-Q filed August 10, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 11, 2026 (estimated)

Metagenomi Therapeutics, Inc.'s trailing-twelve-month revenue fell 50.7% year on year, with a free-cash-flow margin of -392.0%.

Current signal Operating margin compressing: TTM operating margin fell to -415.5%, down 221.7pp year over year.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Net cash. Cash exceeds long-term debt by $0.0bn.

Things to watch

  • Results due soon. Results are expected around 11 November; the share price can move sharply on the day.
  • Revenue shrinking. Revenue fell 50.7% over the last 12 months.
  • Loss-making. Operating margin is -415.5%: costs exceed revenue.
  • Margins narrowing. Operating margin is down 221.7 points on a year ago.
  • Burning cash. Free cash flow was -392.0% of revenue over the last 12 months.
  • Heavy stock-based pay. Stock pay equals 51.4% of revenue: a real cost that cash-flow figures leave out.

Latest results: FY2026 Q1

Filed May 11, 2026
Earnings per share
-$0.73 against an average estimate of -$0.52: missed by 40.4%
Revenue
$1m, down 69.8% on a year earlier
Share reaction
-1.6% in the first session after the results on August 10, 2026, against -0.3% for the S&P 500

Metagenomi Therapeutics' figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-3.2%
  • 1 week-1.6%
  • 1 month-26.0%
  • This year-53.4%
  • 1 year-70.3%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$22.3M
Operating margin
-415.5%
Net margin
-384.6%
EPS (TTM, diluted)
$-2.49

Growth

Revenue growth
−50.7%
Change in growth rate
+1.1 pts
Share count change
+1.0%

Cash

Free cash flow (TTM)
-$85.8M
FCF margin
-392.0%
Stock pay % of revenue
51.4%

Earnings

Last results
August 10, 2026
Next results (est.)
November 11, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Announcement
  2. Results

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Metagenomi Therapeutics, Inc. valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: data-quality checks not passed.

Valuation multiples over time Market data may be delayed

At fiscal year end 20242025Now
Share price$3.61$1.62$0.76
Market value$119m$60m$28m
+ Net debt (− = net cash)−$27m−$42m−$25m
Enterprise value$92m$19m$3m
Multiples
Price / sales 2.3x2.4x1.3x
Price / earnings ———
Price / free cash flow ———
EV / EBITDA ———

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$2.42 −2% $5m −80%
Next −$1.83 +24% $7m +46%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is +11.9% on 90 days ago. In the last 30 days, 0 analysts raised Metagenomi Therapeutics, Inc.'s forecast and 3 cut it.

Consensus EPS forecast Metagenomi Therapeutics, Inc., last 90 days
−$3.00 −$2.00 −$1.00 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$2.16 Current fiscal year, 60 days ago: −$2.42 Current fiscal year, 30 days ago: −$2.42 Current fiscal year, 7 days ago: −$2.42 Current fiscal year, Now: −$2.42 −$2.42 Next fiscal year, 90 days ago: −$2.12 Next fiscal year, 60 days ago: −$1.83 Next fiscal year, 30 days ago: −$1.83 Next fiscal year, 7 days ago: −$1.83 Next fiscal year, Now: −$1.83 −$1.83

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$2.16−$2.12
60 days ago −$2.42−$1.83
30 days ago −$2.42−$1.83
7 days ago −$2.42−$1.83
Now −$2.42−$1.83

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$0.52 −$0.73 −40.4%
Mar 2026 −$0.55 −$0.61 −10.9%
Dec 2025 −$0.58 −$0.60 −2.6%
Sept 2025 −$0.53 −$0.55 −3.1%

Adjusted EPS as companies report it, against the average analyst estimate.

Management guidance

Earnings release, August 10, 2026

No numeric guidance in Metagenomi Therapeutics, Inc.'s latest earnings release (filed August 10, 2026). Some companies give their outlook only on the earnings call.

Analyst recommendations

5 analysts, Oct 2026
Buy480%
Hold120%
Sell00%

Monthly trend

  1. Oct 2026415
  2. Sep 2026415
  3. Aug 2026415

Counts of recommendations published by analysts covering Metagenomi Therapeutics, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
4.2%
of tradable shares
Days to cover
7.84
at average volume
Short interest, 1 month
−10%
to October 15, 2026
Held by institutions
18%
of shares
Held by insiders
19.0%
of shares
Employees
113
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

What moved the share price

Last 12 months −70.3%

$2.54 on October 31, 2025 to $0.76

ThenNowEffect
Revenue (last 12 months) $34m $22m −33.9%
P/S multiple 2.8x 1.3x −54.6%
Share count 37m 38m −1.0%

Biggest factor: p/s multiple. Loss-making at one end, so the split uses price/sales.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 20252026 to date
Return
MGX−55%−53%
Industry peers (median)−5%−26%
S&P 500+18%+11%
Months that ended higher
MGX33%9%
S&P 50075%46%
Largest fall from a high during the year
MGX−67%−58%
S&P 500−19%−9%

Worst fall since February 9, 2024: 94% from February 14, 2024 to November 2, 2026. Getting back needed a 1523% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$0.76 – $2.42
From 52-week high
−68.8%
vs 50-day average
−27.0%
vs 200-day average
−41.4%
Volatility (1 year)
54%
Beta vs S&P 500
1.55

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
2 up, 10 down
typical move ±8.6%
After a week
3 up, 9 down
typical move ±9.5%
After a month
2 up, 10 down
typical move ±16.9%
Results releasedNext dayS&P 500 next day5 days21 days
August 10, 2026 −1.6% −0.3% −0.8% −6.5%
May 11, 2026 −4.3% +0.1% −9.9% −12.8%
March 5, 2026 −7.5% −1.9% −1.9% −15.0%
November 12, 2025 −22.7% −1.6% −26.8% −25.0%
August 12, 2025 +6.0% +1.4% 0.0% +3.3%
May 13, 2025 −3.2% +0.8% +9.7% −6.5%
March 17, 2025 −10.8% −0.3% −14.9% −19.1%
November 13, 2024 −14.9% −0.6% −25.3% +46.6%
August 14, 2024 −9.8% +2.0% +2.2% −16.9%
May 14, 2024 +3.8% +1.7% +8.4% −8.4%
May 1, 2024 −12.1% +0.6% −3.1% −9.1%
March 27, 2024 −6.8% +0.8% −10.9% −33.5%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Fundamentals

Revenue (TTM) Metagenomi Therapeutics, Inc.
$20M $30M $40M $50M $60M FY23 Q4 FY24 Q2 FY24 Q4 FY25 Q2 FY26 Q1 Revenue (TTM), FY23 Q4: $44.8M Revenue (TTM), FY24 Q1: $47.3M Revenue (TTM), FY24 Q2: $55.9M Revenue (TTM), FY24 Q3: $55.1M Revenue (TTM), FY24 Q4: $52.3M Revenue (TTM), FY25 Q1: $45.3M Revenue (TTM), FY25 Q2: $33.8M Revenue (TTM), FY25 Q3: $30.9M Revenue (TTM), FY25 Q4: $25.2M Revenue (TTM), FY26 Q1: $22.3M $22.3M

Source: SEC EDGAR filings. Retrieved November 1, 2026.

View chart data
Period Revenue (TTM)
FY23 Q4 $44.8M
FY24 Q1 $47.3M
FY24 Q2 $55.9M
FY24 Q3 $55.1M
FY24 Q4 $52.3M
FY25 Q1 $45.3M
FY25 Q2 $33.8M
FY25 Q3 $30.9M
FY25 Q4 $25.2M
FY26 Q1 $22.3M
Revenue growth, TTM YoY Metagenomi Therapeutics, Inc.
-60% -40% -20% 0% 20% FY24 Q4 FY25 Q1 FY25 Q2 FY25 Q3 FY25 Q4 FY26 Q1 Revenue growth, TTM YoY, FY24 Q4: 16.8% Revenue growth, TTM YoY, FY25 Q1: -4.2% Revenue growth, TTM YoY, FY25 Q2: -39.6% Revenue growth, TTM YoY, FY25 Q3: -43.9% Revenue growth, TTM YoY, FY25 Q4: -51.8% Revenue growth, TTM YoY, FY26 Q1: -50.7% -50.7%

Source: SEC EDGAR filings. Retrieved November 1, 2026.

View chart data
Period Revenue growth, TTM YoY
FY24 Q4 16.8%
FY25 Q1 -4.2%
FY25 Q2 -39.6%
FY25 Q3 -43.9%
FY25 Q4 -51.8%
FY26 Q1 -50.7%
Operating margin (TTM) Metagenomi Therapeutics, Inc.
-600% -400% -200% 0% FY23 Q4 FY24 Q2 FY24 Q4 FY25 Q2 FY26 Q1 Operating margin (TTM), FY23 Q4: -175.4% Operating margin (TTM), FY24 Q1: -189.6% Operating margin (TTM), FY24 Q2: -158.2% Operating margin (TTM), FY24 Q3: -160.6% Operating margin (TTM), FY24 Q4: -170.0% Operating margin (TTM), FY25 Q1: -193.7% Operating margin (TTM), FY25 Q2: -271.9% Operating margin (TTM), FY25 Q3: -298.5% Operating margin (TTM), FY25 Q4: -380.9% Operating margin (TTM), FY26 Q1: -415.5% -415.5%

Source: SEC EDGAR filings. Retrieved November 1, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q4 -175.4%
FY24 Q1 -189.6%
FY24 Q2 -158.2%
FY24 Q3 -160.6%
FY24 Q4 -170.0%
FY25 Q1 -193.7%
FY25 Q2 -271.9%
FY25 Q3 -298.5%
FY25 Q4 -380.9%
FY26 Q1 -415.5%
FCF margin (TTM) Metagenomi Therapeutics, Inc.
-400% -300% -200% -100% 0% FY23 Q4 FY24 Q2 FY24 Q4 FY25 Q2 FY26 Q1 FCF margin (TTM), FY23 Q4: -226.2% FCF margin (TTM), FY24 Q1: -229.2% FCF margin (TTM), FY24 Q2: -189.6% FCF margin (TTM), FY24 Q3: -195.9% FCF margin (TTM), FY24 Q4: -214.5% FCF margin (TTM), FY25 Q1: -231.0% FCF margin (TTM), FY25 Q2: -293.0% FCF margin (TTM), FY25 Q3: -299.0% FCF margin (TTM), FY25 Q4: -354.9% FCF margin (TTM), FY26 Q1: -392.0% -392.0%

Source: SEC EDGAR filings. Retrieved November 1, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q4 -226.2%
FY24 Q1 -229.2%
FY24 Q2 -189.6%
FY24 Q3 -195.9%
FY24 Q4 -214.5%
FY25 Q1 -231.0%
FY25 Q2 -293.0%
FY25 Q3 -299.0%
FY25 Q4 -354.9%
FY26 Q1 -392.0%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Mar 2026
Income
Revenue 45 52 25 22
EBITDA −74 −83 −91 −88
Operating income −78 −89 −96 −93
Net income −68 −78 −88 −86
Diluted EPS −$2.00 −$2.36 −$2.36 −$2.30
Growth (year on year)
Revenue — +16.8% −51.8% −50.7%
Margins
EBITDA margin −166.0% −159.7% −359.8% −392.0%
Operating margin −175.4% −170.0% −380.9% −415.5%
Net margin −152.5% −149.3% −348.5% −384.6%
Free-cash-flow margin −226.2% −214.5% −354.9% −392.0%
Cash flow
Cash from operations −91 −109 −89 −87
Capital spending 10 3 1 0
Free cash flow −101 −112 −89 −88
Stock-based pay 7 16 12 11
Free cash flow after stock pay −108 −128 −101 −99
Balance sheet
Cash 141 27 42 25
Total debt 0 0 0 0
Net debt (negative = net cash) −141 −27 −42 −25
Diluted shares 34m 33m 37m 37m

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

2 of 2 checks passed · June 30, 2026
What it owns · $174m
Short-term assets $124mLonger-term assets $49m
What it owes, and who funded it · $174m
Short-term liabilities $28mLonger-term liabilities $34mShareholders' equity $113m
  • Short-term assets cover short-term liabilities $124m of assets due within a year against $28m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $124m short-term assets against $34m of longer-dated liabilities.
  • More cash than debt Cash or debt not separately reported. Not assessable.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
  • Operating profit covers interest at least five times over Interest not separately reported. Not assessable.

From Metagenomi Therapeutics, Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

Diluted share count
+1.0%
year over year
R&D spending
396.7%
of revenue

Competitors: side by side with peers

Closest by revenue in biotechnology
Last 12 months unless stated MGX JANX CRSP ABEO SCYX CELU Median
Revenue, last 12 months $22m $24m $25m $26m $19m $19m $55m
Revenue growth, last 12 months −50.7% >999% −34.3% −87.7% 489.8% −58.1% 12.2%
Revenue growth, 3-year average — 45.7% −47.1% 212.0% −47.9% 7.2% 13.7%
Revenue growth, latest quarter −69.8% >999% >999% >999% −82.8% −5.3% 10.2%
Gross margin — — — 67.1% 26.0% 19.2% 82.9%
Operating margin −415.5% −598.1% <−999% −327.6% −117.6% −264.3% −191.1%
Operating margin, 3-year average −266.3% <−999% <−999% <−999% −592.1% −204.2% −361.6%
Net margin −384.6% −427.5% <−999% −246.4% −53.3% −245.7% −172.8%
Cash from operations / revenue −390.6% −171.9% <−999% −299.5% −69.3% −47.8% −168.8%
Free-cash-flow margin −392.0% −174.7% <−999% −319.5% −69.3% −80.1% −168.1%
Free-cash-flow margin, 3-year average −284.1% <−999% −793.9% <−999% −304.8% −50.3% −306.5%
Stock pay / revenue 51.4% 153.7% 276.8% 45.4% 12.3% 66.5% 20.7%
Change in share count 1.0% 6.2% 10.0% 36.6% 1.9% 24.7% 8.1%

Median of all 185 companies we cover in biotechnology. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Who owns it

Funds buying and selling
Reported value
$7.5M
Institutions reporting
43
Shares held vs prior quarter
▼ 3.1%
Positions opened / closed
4 / 7

Top buyers and sellers, Q2 2026: 16 institutions bought and 20 sold ; the biggest buyer was Wells Fargo & Company (+177K shares) and the biggest seller Jacobs Levy Equity Management, Inc (−222K). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Vanguard Capital Management LLC $1.3M 1.1M 17.2% ▲ 1.9%
Renaissance Technologies LLC $883,456 742K 11.9% ▼ 5.8%
Catalio Capital Management, LP $629,502 529K 8.4% 0.0%
Peapod Lane Capital LLC $624,779 525K 8.4% ▲ 1.6%
Two Sigma Investments, LP $611,304 514K 8.2% ▲ 3.4%
Bridgeway Capital Management, LLC $476,357 400K 6.4% ▲ 1.1%
Wells Fargo & Company $451,614 380K 6.1% ▲ 87.7%
Geode Capital Management, LLC $343,672 289K 4.6% ▼ 19.4%
Pura Vida Investments, LLC $314,625 264K 4.2% 0.0%
Blackrock, Inc. $306,581 258K 4.1% ▲ 11.9%
Vanguard Fiduciary Trust Co $203,789 171K 2.7% ▲ 0.6%
Jacobs Levy Equity Management, Inc $190,400 160K 2.6% ▼ 58.1%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Metagenomi Therapeutics, Inc.'s complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $23,401 2 trades by 1 insider, last 12 months Insider sales History → $33,076 13 trades by 4 insiders · 0% under pre-set plans
Net ▼ $9,675 net selling
Insider Date Trade Shares Price Value
Reid Laurence Director September 9, 2026 Buy 117 $1.18 $138
Reid Laurence Director September 9, 2026 Buy 19,883 $1.17 $23,263
Wapnick Pamela Chief Financial Officer September 8, 2026 Sell 1,911 $1.16 $2,217
Irish Jian See Remarks September 8, 2026 Sell 2,140 $1.16 $2,482
Wein Matthew See Remarks September 8, 2026 Sell 358 $1.16 $415
Wein Matthew See Remarks June 5, 2026 Sell 558 $1.30 $725
Irish Jian See Remarks June 5, 2026 Sell 3,737 $1.30 $4,858
Wapnick Pamela Chief Financial Officer June 5, 2026 Sell 2,884 $1.30 $3,749
Irish Jian Chief Executive Officer March 5, 2026 Sell 1,607 $1.60 $2,571
Wein Matthew See Remarks March 5, 2026 Sell 482 $1.60 $771
Wapnick Pamela Chief Financial Officer March 5, 2026 Sell 1,581 $1.60 $2,530
Irish Jian Chief Executive Officer December 5, 2025 Sell 1,602 $1.77 $2,836

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around November 11, 2026 estimated from the company's past filing pattern, not announced

  • August 10, 2026
  • May 11, 2026
  • March 5, 2026
  • November 12, 2025
  • August 12, 2025
  • May 13, 2025

Recent SEC filings

Data status

When each part of this page on Metagenomi Therapeutics, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Metagenomi Therapeutics, Inc. in brief

What does Metagenomi Therapeutics, Inc. do?
Metagenomi Therapeutics, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
What is Metagenomi Therapeutics, Inc.'s stock ticker?
Metagenomi Therapeutics, Inc. trades under the ticker MGX on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Metagenomi Therapeutics, Inc.'s revenue, and how fast is it growing?
Over its most recent trailing twelve months, Metagenomi Therapeutics, Inc. reported revenue of $22.3M, 50.7% lower than a year earlier, according to its SEC filings.
What is Metagenomi Therapeutics, Inc.'s free cash flow?
Metagenomi Therapeutics, Inc.'s free-cash-flow margin is -392.0% of revenue over the trailing twelve months.
Who are Metagenomi Therapeutics, Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Vanguard Capital Management LLC, Renaissance Technologies LLC and Catalio Capital Management, LP. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Metagenomi Therapeutics, Inc.'s market cap?
On November 2, 2026, Metagenomi Therapeutics, Inc.'s market capitalisation was about $28.2M and net debt of -$25.3M. Market figures come from third-party market data and may be delayed.
Who are Metagenomi Therapeutics, Inc.'s competitors?
In our Biotechnology peer group, the companies closest to Metagenomi Therapeutics, Inc. are Janux Therapeutics, Inc., Crispr Therapeutics AG, Abeona Therapeutics Inc., Scynexis Inc and Celularity Inc. The side-by-side comparison below sets their revenue, margins and growth against Metagenomi Therapeutics, Inc.'s.
Are insiders buying or selling Metagenomi Therapeutics, Inc. stock?
Over the last 12 months, Metagenomi Therapeutics, Inc.'s directors and officers reported 2 open-market purchases and 13 sales on Form 4. The insider trading page charts every trade.
When is Metagenomi Therapeutics, Inc.'s next earnings date?
Around November 11, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Metagenomi Therapeutics, Inc. announces its own schedule.